The market for Vulvovaginal Candidiasis (VVC) was valued at USD 971.51 million in 2021 and is anticipated to grow at a 4.2% CAGR in terms of revenue during the projected period. The rise in vulvovaginal candidiasis infections in women around the world, rising regulatory approvals for vulvovaginal candidiasis treatments, and an increase in clinical research studies into vulvovaginal candidiasis...